Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by GameChangerBeton May 19, 2021 6:59pm
224 Views
Post# 33235084

RE:RE:RE:What is the scenario

RE:RE:RE:What is the scenario
StockingUp21 wrote:

I bet 90% of people who invest here did not know they don't own IP. So shady. Almangement working for themselves on the side before this while we fund research. 

 

GameChangerBet wrote:

 

Notthatbright wrote: should the shareholdres vote against amalgamation?


You certainly want to amalgamate. You want your shares to own the IP.
Any potential future aquiring event will likely require the IP, package deal.

In addition to that, you absolutely want senior management to own the same common shares you do, as opposed to owning shares in AH where they sit back and collect royalties that ATE would have owed them from future sales. Everyone is now on the same page.
What's good for the bosses, will be good for us shareholders.




Don't confuse lack of adequate work to understand exactly what you're investing in with the word shady.
I imagine you simply assumed they owned the IP? Didn't bother to check? Didn't know to even check? Didn't know it was even a thing?
These are not signs of shady, these are signs of not having a complete understanding of what you invested in.
All information was, and is public. 
This is not a blame game, it is a matter of responsibility of understanding your investment.
I bet when brokerages were involved with them to do financings, they surely knew about the Holding company. You know why? Beacuse institutions do their work thoroughly before dropping a dime. 
Get it?
Institution vs Retail
One knows exactly what the fine print states, the other makes decisions on how they feel that day.

<< Previous
Bullboard Posts
Next >>